XY0206
Phase 3Small molecule
XY0206 is one of 78 small molecule programs targeting ART. It is currently in Phase 3.
2
Indications
5
Total Trials
2
Active Trials
77
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
96 competitors in ART
#DrugCompanyPhaseTrials
1Belamaf
GSKPhase 3
Venclexta
AbbViePhase 3
Rituxan
RochePhase 3
Lorelco
SanofiPhase 3
Brukinsa
BBeOne Medicines
Phase 3
Treanda
AAzurity Pharmaceuticals
Phase 3
Toradol
JJavelin Pharmaceuticals
Phase 3
Attruby
NNavire Pharma Inc., a BridgeBio company
Phase 3
Cysteine Hydrochloride
NovartisPhase 2
Noradrenaline
IInstitute of Liver and Biliary Sciences, India
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Relapsed or Refractory1 trial
Acute Myeloid Leukemia1 trial
Advanced or Metastatic Solid Tumour1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for XY0206. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details